Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04212169 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis
A Phase 2 study of Atopic Dermatitis, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 148
- Enrollment target
- 20
- Study locations
NCT04212169: Completed Phase 2 study of Atopic Dermatitis, sponsored by AstraZeneca.
NCT04212169 is a Phase 2 study of Atopic Dermatitis that has completed, run by AstraZeneca. The registered enrollment target is 148 participants, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (76% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04212169, a Phase 2 study of Atopic Dermatitis, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 148 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a research study to determine the efficacy and safety of investigational drug MEDI3506 for the treatment of adult subjects with Atopic Dermatitis.
Primary Outcome
The EASI evaluates 4 anatomic regions for severity and extent of key disease signs and focuses on the acute and chronic signs of inflammation (ie, erythema, edema, papulation, excoriation, and lichenification). The maximum score is 72, with higher values indicating more severe disease. Analysis was performed using mixed effect model for repeated measures and MCP-mod dose response model.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MEDI3506
Study Locations (20)
Other
- Research Site - Box Hill
- Research Site - Carlton
- Research Site - East Melbourne
- Research Site - Fremantle
- Research Site - Berlin
- Research Site - Dresden
- Research Site - Hamburg
Florida
- Research Site - Jacksonville
- Research Site - Miami
- Research Site - Orlando
Texas
- Research Site - San Antonio
- Research Site - San Antonio
Alabama
- Research Site - Birmingham
California
- Research Site - Santa Monica
Louisiana
- Research Site - Baton Rouge
North Carolina
- Research Site - Charlotte
Oklahoma
- Research Site - Tulsa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2019-12-09 |
| Est. Completion | 2022-09-20 |
| Phase | Phase 2 |
What the finished NCT04212169 record still lists
NCT04212169 is an interventional study that assigns participants to a tested intervention. The registered 148 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04212169 names 20 study sites across 11 states, led by Other, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT04212169 about?
NCT04212169 is a clinical study titled "Efficacy and Safety of MEDI3506 in Adult Subjects With Atopic Dermatitis". This is a research study to determine the efficacy and safety of investigational drug MEDI3506 for the treatment of adult subjects with Atopic Dermatitis.
What is the current status of trial NCT04212169?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 148 participants. The study started on 2019-12-09. Estimated completion is 2022-09-20.
What conditions does trial NCT04212169 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT04212169?
The interventions under investigation include: Placebo (DRUG), MEDI3506 (DRUG).
Who is sponsoring clinical trial NCT04212169?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04212169 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Louisiana, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04212169's enrollment target sits among peer trials
148 73rd of 150 higher than 78 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00739362 · 148 participants · Phase 2
Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment
- NCT03161223 · 148 participants · Phase 1
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
- NCT03858231 · 148 participants · Phase 4
Opioids Versus Non-Opioids Postoperative After Knee Arthroscopic Surgery
- NCT04486352 · 148 participants · Phase 1
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI